These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34727187)

  • 1. How I treat high-risk multiple myeloma.
    Zamagni E; Barbato S; Cavo M
    Blood; 2022 May; 139(19):2889-2903. PubMed ID: 34727187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
    Landgren O; Lu SX; Hultcrantz M
    Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
    Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; Ludwig H; Chen W; Cavo M; Harousseau JL; Lentzsch S; Hillengass J; Palumbo A; Orfao A; Rajkumar SV; Miguel JS; Avet-Loiseau H
    Lancet Oncol; 2016 Aug; 17(8):e328-e346. PubMed ID: 27511158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):430-435. PubMed ID: 38964916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
    Mina R; Bonello F; Oliva S
    Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
    Paiva B; Puig N; García-Sanz R; San Miguel JF;
    Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
    J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
    Alonso R; Cedena MT; Gómez-Grande A; Ríos R; Moraleda JM; Cabañas V; Moreno MJ; López-Jiménez J; Martín F; Sanz A; Valeri A; Jiménez A; Sánchez R; Lahuerta JJ; Martínez-López J
    Am J Hematol; 2019 Aug; 94(8):853-861. PubMed ID: 31074033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
    Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep Response in Multiple Myeloma: A Critical Review.
    Fulciniti M; Munshi NC; Martinez-Lopez J
    Biomed Res Int; 2015; 2015():832049. PubMed ID: 26783530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUK
    Brown S; Sherratt D; Hinsley S; Flanagan L; Roberts S; Walker K; Hall A; Pratt G; Messiou C; Jenner M; Kaiser M;
    BMJ Open; 2021 Mar; 11(3):e046225. PubMed ID: 33762245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
    Paiva B; Cedena MT; Puig N; Arana P; Vidriales MB; Cordon L; Flores-Montero J; Gutierrez NC; Martín-Ramos ML; Martinez-Lopez J; Ocio EM; Hernandez MT; Teruel AI; Rosiñol L; Echeveste MA; Martinez R; Gironella M; Oriol A; Cabrera C; Martin J; Bargay J; Encinas C; Gonzalez Y; Van Dongen JJ; Orfao A; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF;
    Blood; 2016 Jun; 127(25):3165-74. PubMed ID: 27118453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.